UK government to build on biotechnology success:
This article was originally published in Clinica
Executive Summary
The UK government has set up a team of academic and business leaders to examine how the UK can maintain a competitive lead in the biotechnology industry. The science minister, Lord Sainsbury, will lead the two-month review, which will consider the growth of clusters of biotechnology companies in the UK and whether there are any barriers to their future development. The team, which includes Merlin Ventures' Dr Chris Evans, will report on the action needed to ensure biotechnology continues to flourish. The government estimates that the European market for biotech products will be worth at least £100 billion ($161 billion) by 2005.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.